Sepsis and cytokines: Current status
Sepsis and cytokines: Current status
复制标题
DOI：
10.1093/bja/77.1.110
复制
发表时间：
1996-07-01
影响因子：
9.8
通讯作者：
Christman, JW
中科院分区：
文献类型：
--
作者：
Blackwell, TS;Christman, JW
脓毒症是由宿主对感染的过度全身炎症反应引起的一系列临床体征和症状。这种炎症反应主要由释放到体循环中的细胞因子介导。特定细胞因子TNF α、IL-1 β、IL-6和IL-8的血浆浓度在人脓毒症中经常升高，并且细胞因子浓度与脓毒症的严重程度和结果相关。除了促炎性细胞因子外，脓毒症患者还大量产生可溶性细胞因子受体、细胞因子受体拮抗剂和抗炎性细胞因子;然而，这些分子在脓毒症中的具体作用仍不明确。细胞因子和嘌呤中和分子的复杂相互作用可能决定了脓毒症的临床表现和病程。干预这一系列事件以改变宿主炎症反应可能被证明是败血症的有益治疗策略，但目前测试的抗细胞因子疗法在很大程度上是不成功的。
Sepsis is a constellation of clinical signs and symptoms resulting from excessive systemic host inflammatory response to infection. This inflammatory response is largely mediated by cytokines, which are released into the systemic circulation. Plasma concentrations of specific cytokines, TNF alpha, IL-1 beta, IL-6 and IL-8 are frequently elevated in human sepsis and cytokine concentrations correlate with severity and outcome of sepsis. In addition to pro-inflammatory cytokines, soluble cytokine receptors, cytokine receptor antagonists and counter-inflammatory cytokines are also produced in large quantities in patients with sepsis; however, the specific role of these molecules in sepsis remains undefined. A complex interaction of cytokines and cytokine-neutralizing molecules probably determines the clinical presentation and course of sepsis. Intervening in this sequence of events to modify the host inflammatory responses may prove to be a beneficial treatment strategy for sepsis, but currently tested anticytokine therapies have been largely unsuccessful.